Concord Biotech Limited (NSE:CONCORDBIO)
1,427.70
-21.00 (-1.45%)
Nov 21, 2025, 3:30 PM IST
Concord Biotech Revenue
Concord Biotech had revenue of 2.47B INR in the quarter ending September 30, 2025, a decrease of -20.35%. This brings the company's revenue in the last twelve months to 11.25B, up 3.63% year-over-year. In the fiscal year ending March 31, 2025, Concord Biotech had annual revenue of 12.00B with 18.01% growth.
Revenue (ttm)
11.25B
Revenue Growth
+3.63%
P/S Ratio
13.27
Revenue / Employee
7.16M
Employees
1,571
Market Cap
149.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | 6.17B | 1.05B | 20.42% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |